Eli Lilly has inked the deal to purchase AtaiBeckley for $2.8 billion to continue its acquisition spree in a mental health space that is being pursued by a host of players, such as Johnson & Johnson, with interest, including the psychedelic firm.
The drug being developed by AtaiBeckley is called BPL-003 and is an intranasal (sniffed) version of the psychedelic substance 5-MeO-DMT. The substance is a stimulator of the serotonin system that controls mood and is present in certain plants and animals. BPL-003 was shown to be statistically significant in a phase 2b trial, which was performed on patients who had treatment-resistant depression (TRD) and began to show improvements from day 2. The effects lasted until Day 57.
Lilly has agreed to pay $6.75 per share in cash for the purchase of AtaiBeckley, a 40 percent premium over the 30-day volume-weighted average trading price of the biotech. The AtaiBeckley stock price ended at $5.36 on Wednesday.
An AtaiBeckley investor may get an additional $2.50 per share if BPL-003 and one more candidate, the DMT buccal movie possession VLS-01, accomplish a variety of milestones. Lilly has linked $1 per share to the initiation of phase 3 trials of VLS-01 and another $1 per share to the asset being approved for use in the United States and being rescheduled. An additional $50 per share depends on the approval and rescheduling of BPL-003.
Milestones covered by the contingent value right, which Lilly will give AtaiBeckley shareholders, could add $1 billion to the value of the deal. In the event that the milestones are met, Lilly would be a competitor with J&J for the TRD market.
J&J’s Spravato is among two approved TRD medications, along with a combo of two drugs that can be used separately as generics. The J&J product is an isomer of ketamine that can cause dissociative effects, and patients must be monitored for 2 hours after the injection. In the phase 2b trial, the majority of patients were discharged from the hospital after 90 minutes of BPL-003 treatment.
The discharge schedule makes BPL-003 fit into the treatment infrastructure set up for Spravato. In March, at an investor day, Srinivas Rao, the CEO of AtaiBeckley, stated that the company had “been taking the lessons from past interventional experiences like Spravato and developing treatment approaches that are equally effective or even more effective, but much less complex.”
BMO Capital Markets analysts said they were impressed with the transaction in a note to investors. The analysts expressed optimism that the transaction would bring “differentiated” exposure in psychiatry and bolster Lilly’s broader strategy to diversify its product mix away from its core cardiometabolic franchise, after Bloomberg reported that the firm was in talks to acquire the drugmaker.
The analysts also highlighted the growing regulatory support for psychedelic drugs in treating mental health disorders.
AtaiBeckley has become the center of one of the largest neuroscience transactions after Eli Lilly agreed to pay $2.8 billion upfront to strengthen its position in psychedelic mental health therapies. The agreement highlights the growing interest in innovative treatments for depression, anxiety, and other psychiatric disorders while positioning AtaiBeckley as a key contributor to the future of mental health drug development.
Why the AtaiBeckley Deal Matters
The acquisition reinforces AtaiBeckley’s value within the rapidly expanding mental health market. By combining advanced psychedelic research with Lilly’s global development and commercialization capabilities, AtaiBeckley could accelerate the development of next-generation psychiatric therapies and compete more effectively in an increasingly competitive neuroscience sector.
The $2.8 billion agreement marks a major milestone for AtaiBeckley and signals growing pharmaceutical interest in psychedelic mental health treatments. By combining innovative neuroscience research with Lilly’s global capabilities, AtaiBeckley is positioned to play an important role in developing the next generation of therapies for patients living with serious mental health disorders.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
